Ridgeback Capital — 2024 Investments

2 investments dated 2024 · listed companies and verified rows first · show all

Bicyclebicycletherapeutics.com in 𝕏NASDAQ: BCYCMay 2024

Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.

BiotechHealthtechCambridge, GB

Gregory Winter(Director)inNIGEL CROCKETT(Executive Officer)inNICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)MICHAEL SKYNNER(Executive Officer)in

Co-investorsAhren Innovation Capital Astellas Venture Management LLC Cambridge Innovation Capital Dementia Discovery Fund Longwood Fund SR One Capital Management +4 more

Hinge Biohingebio.com inDec 2024

Hinge Bio is a biotechnology company developing next-generation therapeutics based on its GEM-DIMER platform, aimed at improving efficacy and reducing resistance and side effects.

BiotechHealthtechBurlingame, US

Daniel J. Capon(Director)Carin Mueller Rollins(Co-Founder & Chief Operating Officer)Harold E. Selick, PhD(Executive Officer, Director)Miriam Siekevitz(Executive Officer)inHarold E. "Barry" Selick(Chief Executive Officer & Director)Paul Brunetta(Chief Medical Officer)in

Co-investorsPoint72 Agent Capital Baruch Future Ventures InVivium Capital

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.